UNSPSC 51343802: Abacavir/lamivudine/zidovudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51343802 Abacavir/lamivudine/zidovudine, a Commodity code, shows a significant mismatch between its nominal scope — a specific antiretroviral combination therapy — and the work actually being solicited under it in recent state and local opportunities. The source records instead document procurement of naloxone and drug deactivation systems, medical and first aid supplies for fire departments, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription program implementation consulting. None of these solicitations align with the code's stated pharmaceutical product. The issuing bodies span state health and human services departments (Texas HHS Commission, Minnesota Department of Administration), county health agencies (Seminole County, Florida), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (MMCAP), indicating fragmented demand across health agencies, emergency services, and pharmacy benefit administration functions.

Recent activity appears in Florida, Texas, Minnesota, and Oregon (through MMCAP participation). Representative recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with quarterly deliveries and a July 26, 2023 response deadline; the City of Tampa's IFB 26-P-00145 for medical and first aid supplies for the Fire Department Rescue Division, with a $700,000 estimated value and a sheltered small local business enterprise set-aside (5 percent bid discount capped at $10,000); the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with an RFQ response deadline of March 26, 2026; and the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities, posted April 3, 2026. The code shows little relevant recent activity aligned with its stated pharmaceutical scope and should be treated as misclassified or dormant for procurement-targeting purposes.